Therapeutic Inertia in an Insured Population with Type 2 Diabetes in the United States: A Retrospective Cohort Study
Open Access
- 8 September 2025
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (10) , 2009-2023
Abstract
Introduction This study examines the characteristics of adults with type 2 diabetes (T2D) who were not initially treated with an antihyperglycemic agent (AHA). Methods The analyses used Optum de-identified Market Clarity data from January 2013 through September 2023. The US study included nonpregnant adults with T2D who were continuously insured from 1 year prior through 5 years post diagnosis and did not fill a prescription for an AHA in the year after their initial T2D diagnosis. Differences between those treated in years 2–5 with an AHA (delayed treatment) and those untreated with an AHA for 5 years post diagnosis (untreated) were examined descriptively and using multivariable analyses. Results Out of 186,259 adults with T2D, 56.7% (N = 105,533) did not fill a prescription for an AHA in the year after diagnosis and were included in the study. Of these 105,533 adults (mean age 59.6 years; 51.4% female), 75.0% were untreated for the entire 5 years post diagnosis. In the delayed treatment group, metformin was the most common first-line therapy (72.9%), and 83.0% of those who initiated monotherapy never received additional classes of AHAs. Compared to the delayed treatment group, the untreated group had significantly higher rates of incident cardiovascular outcomes and all-cause direct total costs ($118,191 vs $108,687; P < 0.05). Conclusion Over 50% of adults diagnosed with T2D were untreated with an AHA in the first year post diagnosis, and most of those who went untreated the first year remained untreated after 5 years. Among the delayed treatment patients, the majority did not use additional AHA classes besides their index therapy in the post-period. These findings suggest that therapeutic inertia affects a significant percentage of individuals with T2D. Given the untreated group’s significantly worse cardiovascular outcomes and higher medical costs, these findings highlight a potential unmet need in the years immediately following T2D diagnosis.Keywords
Funding Information
- Eli Lilly and Company
This publication has 35 references indexed in Scilit:
- Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbiditiesJournal of Diabetes and its Complications, 2015
- Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetesDiabetes Research and Clinical Practice, 2015
- Sex differences in anxiety and depression clinical perspectivesFrontiers in Neuroendocrinology, 2014
- Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2013
- Time to initiation of oral antihyperglycemic and statin therapy in previously untreated patients with type 2 diabetes in the United StatesCurrent Medical Research and Opinion, 2013
- Overweight, Obesity, and DepressionArchives of General Psychiatry, 2010
- Association Between Obesity and Psychiatric Disorders in the US Adult PopulationArchives of General Psychiatry, 2006
- Impact of Long-Term Complications on Quality of Life in Patients with Type 2 Diabetes not Using InsulinValue in Health, 2001
- Identifying Persons with Diabetes Using Medicare Claims DataAmerican Journal of Medical Quality, 1999
- Onset of NIDDM occurs at Least 4–7 yr Before Clinical DiagnosisDiabetes Care, 1992